BiotechTube

eFT508

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple Negative Breast Cancer

Conditions

Triple Negative Breast Cancer, Hepatocellular Carcinoma

Trial Timeline

Nov 21, 2017 → Jan 22, 2019

NCT ID
NCT03318562

About eFT508

eFT508 is a phase 2 stage product being developed by eFFECTOR Therapeutics for Triple Negative Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03318562. Target conditions include Triple Negative Breast Cancer, Hepatocellular Carcinoma.

What happened to similar drugs?

1 of 20 similar drugs in Triple Negative Breast Cancer were approved

Approved (1) Terminated (1) Active (18)
✅Taxane and Carboplatin + Short-term SintilimabInnovent BiologicsApproved
🔄Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
🔄Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
🔄Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
🔄Sacituzumab Govitecan-hziy + Pembrolizumab + Paclitaxel + nab-Paclitaxel + Gemcitabine + CarboplatinMerckPhase 3
🔄Pembrolizumab + Sacituzumab tirumotecan + CapecitabineMerckPhase 3
🔄pembrolizumab + capecitabine + eribulin + gemcitabine + vinorelbineMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
5
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT03690141Phase 2Terminated
NCT03318562Phase 2Terminated
NCT02605083Phase 1/2Terminated

Competing Products

20 competing products in Triple Negative Breast Cancer

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
No drugDaiichi SankyoPre-clinical
30
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35
Abemaciclib + BicalutamideEli LillyPhase 2
42
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
34
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Camrelizumab + Nab paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
31
SHR-1210 + Apatinib +FluzoparibJiangsu Hengrui MedicinePhase 1
29
Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
40
Combination of Veliparib + LapatinibAbbViePre-clinical
26
Capivasertib + ItraconazoleAstraZenecaPhase 1
29
Datopotamab Deruxtecan (Dato-DXd) + DurvalumabAstraZenecaPhase 2
42
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447AstraZenecaPhase 1/2
36
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + CarboplatinAstraZenecaPhase 1
29
Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
44
Olaparib Oral Product + Olaparib Oral Product in combination with DurvalumabAstraZenecaPhase 2
35
Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecanAstraZenecaPhase 1/2
36